Fed. Cir. Docket No. 2024-2325
LOURIE, LINN, HUGHES
July 9, 2026

Brief Summary: Wyeth’s claims invalidated for lack of enablement because the specification did not sufficiently disclose a “unit dosage” producing a therapeutic effect in a patient, or teach how to make that determination.

Summary: Wyeth asserted claims 1, 3, and 9 of U.S. Patent No. 10,603,314 and claim 1 of U.S. Patent No. 10,596,162 against AstraZeneca’s (AZ) irreversible EGFR inhibitor Tagrisso (osimertinib), alleging induced infringement. The FC panel considered ’314 claim 1, directed to a “method for treating gefitinib and/or erlotinib resistant non-small cell lung cancer” (NSCLC) by “administering daily to the patient” a “unit dosage” of an irreversible EGFR inhibitor “that covalently binds to cysteine 773” of EGFR (or cysteine 805 of erb-B2). The specification states that the inhibitor “may be any compound which binds to cysteine 773,” describes in vitro experiments with three compounds (EKB-569, HKI-357, and HKI-272), and states that “in general, satisfactory results are obtained” at daily dosages of “about 0.5 to about 1000 mg/kg,” with a total daily dosage “projected to be from about 1 to 1000 mg, preferably from about 2 to 500 mg.” Before trial, the DC adopted the specification’s definition of “unit dosage” as “physically discrete units suitable as unitary dosage for the subject, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect.” A jury found the claims infringed (by inducement) and not invalid and awarded $107.5 million in damages, but the DC granted JMOL of invalidity for lack of enablement. The DC concluded that the claims do not require “ideal or optimal dos[ing]” as the FDA requires, but do require “that the ‘unit dosage’ ‘produce[s] the desired therapeutic effect’ in a patient.” It also found that the specification discloses no working examples and that AZ presented unrebutted evidence that some of the disclosed doses would be toxic.

In affirming, the FC panel rejected Wyeth’s argument, based on United Therapeutics (FC 2023), that the DC had imported FDA-type safety and efficacy requirements post-verdict. The claims require more than “killing cancer cells” because “administering daily” to a “patient” must be given meaning (Merck v. Teva, FC 2005), but not “full-blown FDA-type clinical safety standards,” and the DC’s post-verdict “elaboration” permissibly “clarif[ied] what was inherent in the construction” (Cordis, FC 2011).  On enablement, the FC panel held that the specification must teach how to determine a daily “unit dosage” producing a therapeutic effect in a patient “across the full scope of claimed compounds without undue experimentation,” but instead left “dosage determination entirely to the skilled artisan, which in effect requires experimentation” (e.g., no guidance on extrapolating from in vitro results to in vivo dosing) (Amgen, SCOTUS 2023; Baxalta, FC 2023; Idenix, FC 2019 (“[i]t is the specification, not the knowledge of one skilled in the art, that must supply the novel aspects of an invention”)).  Unrebutted testimony, including from Wyeth’s own experts and a co-inventor, showed that the disclosed ranges exceed the maximum tolerated human dose for at least two of the three disclosed compounds, which the FC panel found “weighs heavily in favor of non-enablement” (Atlas Powder, FC 1984).  The FC panel acknowledged that method-of-treatment claims may disclose dose ranges without clinical data, leaving safety and efficacy to the FDA, but explained that here, “perhaps because of close prior art,” the claims were limited to dosage forms administered to patients, while the patents disclosed “only a broad range of doses some of which were shown to be toxic” and “no actual dosages for any compound within the scope of the claims.” Having affirmed invalidity, the FC panel did not reach Wyeth’s appeal on pre-issuance damages and provisional rights under 35 U.S.C. § 154(d).

Patrick Halloran

Pat has a Ph.D. in Microbiology and Immunology from The University of Health Sciences / The Chicago Medical School (now the Rosalind Franklin Institute (North Chicago, IL) (1994)). He also completed post-doctoral studies at The National Cancer Institute (1994-1996) where he developed novel…

Pat has a Ph.D. in Microbiology and Immunology from The University of Health Sciences / The Chicago Medical School (now the Rosalind Franklin Institute (North Chicago, IL) (1994)). He also completed post-doctoral studies at The National Cancer Institute (1994-1996) where he developed novel approaches for gene therapy of melanoma. Pat has been an attorney (IL) since 1999 after graduating from Chicago-Kent College of Law, which was recently ranked as one of the top five law schools for Intellectual Property in the U.S. (U.S. News and World Report link). Pat also has a B.A. in Biology from Augustana College (Rock Island, IL; 1989) where he was on two NCAA Division III National Championship football teams (1985, 1986). He currently resides in Center Valley, PA.